Key result
Antiplatelet responsiveness testing fails to improve major cardiovascular events prediction over standard risk factors in stable outpatients.
Why the study?
Data on the biological response to antiplatelet drugs in stable cardiovascular patients are scarce, and the added predictive value of specific and aggregation-based platelet function assays relative to common predictors has rarely been addressed.
Does biological antiplatelet drug responsiveness testing predict recurrent MACEs in stable cardiovascular outpatients?
Cohort (n=771)
Does biological antiplatelet drug responsiveness testing predict recurrent MACEs in stable cardiovascular outpatients?
Platelet function testing does not provide incremental predictive value over common cardiovascular risk factors for MACE recurrence in stable cardiovascular outpatients.
Answers are grounded in this paper and cite their sources.
Platelet function testing adds no incremental MACE prediction in stable outpatients; leaves open utility in acute or high-risk settings.
BACKGROUND: The biological response to antiplatelet drugs has repeatedly been shown to predict the recurrence of major adverse cardiovascular events (MACEs). However, most studies involved coronary artery disease patients with recent vessel injury shortly after the initiation of antiplatelet therapy. Data on stable cardiovascular patients are scarce, and the added predictive value of specific assays (the vasodilator phosphoprotein assay for the clopidogrel response and serum thromboxane B2 for the aspirin response) and aggregation-based assays relative to common predictors has rarely been addressed. METHODS AND RESULTS: Stable cardiovascular outpatients participating in the Antiplatelet Drug Resistances and Ischemic Events (ADRIE) study (n=771) were tested twice, at 2 separate visits, with specific and aggregation-based assays. Follow-up lasted 3 years, and <1% of patients were lost to follow-up. MACEs were adjudicated by an independent committee. Multivariate survival analyses included relevant variables identified in univariate analysis and platelet function test results. The C-index was used to express the prognostic value of various multivariate models. MACEs, the primary end point, occurred in 16% of patients. Hypertension, smoking, older age, and elevated low-density lipoprotein cholesterol were predictive of MACE recurrence, with a C-index of 0.63 (P<0.001). Neither the specific nor the aggregation-based assays added significant predictive value for the primary end point. CONCLUSIONS: Biological antiplatelet drug responsiveness, measured with specific or aggregation-based assays, has no incremental predictive value over common cardiovascular risk factors for MACE recurrence in stable cardiovascular outpatients. These results do not support platelet function testing for MACE risk evaluation in stable cardiovascular patients. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00501423.
No takes yet. Share an insight, caveat, or question.
Reny et al. (2012) conducted a cohort in Stable cardiovascular disease (n=771). Biological antiplatelet drug responsiveness testing was evaluated on Major adverse cardiovascular events (MACEs). Biological antiplatelet drug responsiveness testing did not add significant predictive value over common risk factors for major cardiovascular events recurrence in stable cardiovascular outpatients.
Synapse has enriched 10 related papers. Consider them for comparative context: